|
| Press Releases |
|
 |
|
| Wednesday, May 7, 2025 |
|
|
Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China |
| Everest Medicines (HKEX: 1952.HK) today announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National Medical Products Administration (NMPA). more info >> |
|
| Tuesday, April 22, 2025 |
|
|
Everest Medicines Announces Approval of 'B' Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong Limited (the 'Stock Exchange') has approved the Company's application to remove the "B" marker from its stock short name, as the company has satisfied the requirements of the listing rules at the Stock Exchange. more info >> |
|
| Friday, March 7, 2025 |
|
|
Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation |
| Everest Medicines' stock (1952.HK) surged today, opening higher and maintaining strong momentum throughout the trading day. By market close, the stock had risen 20.12% to HK$60.6, bringing the company's total market capitalization to HK$19.791 billion. more info >> |
|
| Wednesday, February 19, 2025 |
|
|
Goldman Sachs Raises Everest Medicines' Target Price to HK$48.32 on Stronger Commercial and R&D Outlook |
| Goldman Sachs' latest report on China's biotechnology sector highlights Everest Medicines (1952.HK) as a company on track to achieve EBITDA break-even by the end of 2025. This outlook is driven by the accelerated commercialization of Nefecon(R), which was recently included in China's National Reimbursement Drug List (NRDL). more info >> |
|
| Thursday, January 2, 2025 |
|
|
Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy |
| Everest Medicines (HKEX 1952.HK, Everest , or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that with the official implementation of the latest update of the National Reimbursement Drug List ('NRDL') on January 1, 2025, NEFECON will apply the NRDL pricing, which will benefit more IgA nephropathy (IgAN) patients. more info >> |
|
| Wednesday, December 18, 2024 |
|
|
Everest Medicines Announces the First Prescription of VELSIPITY(R) in the Greater Bay Area |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription for VELSIPITY(R) has been written at Foshan Fosun Chancheng Hospital in Guangdong, under the "Hong Kong and Macau Medicine and Equipment Connect" policy, which marks the official beginning of this new therapy benefiting patients in mainland China. more info >> |
|
| Tuesday, December 17, 2024 |
|
|
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the National Medical Products Administration (NMPA) of China has officially accepted the New Drug Application (NDA) for VELSIPITY (etrasimod) for the treatment of patients with moderately to severely active ulcerative colitis (UC). VELSIPITY is an effective and convenient, once-daily, oral treatment for patients with moderately to severely active UC. more info >> |
|
| Thursday, December 12, 2024 |
|
|
Everest Medicines Announces the First Prescription of VELSIPITY(R) Issued in Macau |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription of VELSIPITY(R) (etrasimod) has been issued on December 11th at Kiang Wu Hospital in Macau. more info >> |
|
| Wednesday, December 11, 2024 |
|
|
Everest Medicines: Accelerating Innovation in Renal Disease to Forge a Path Toward Biopharma Leadership |
| As reported by the South China Morning Post today, Everest Medicines (HKEX 1952.HK) is accelerating its journey to become a leading biopharmaceutical company in the Asia-Pacific region, driven by robust R&D capabilities and exceptional commercialization expertise. more info >> |
|
| Wednesday, December 4, 2024 |
|
|
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy |
| Everest Medicines (HKEX 1952.HK,"Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced positive results in the ongoing Phase 1b/2a clinical trial for the treatment of primary membranous nephropathy (pMN) with EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Urban Land Institute Moves into The Executive Centre at 28 Stanley Street, Central, Hong Kong 
Oct 9, 2025 10:00 HKT/SGT
|
|
|
uSMART Group to Add 7 Physical Service Centres Within 3 Months
Oct 8, 2025 17:25 HKT/SGT
|
|
|
HKTDC and HKSTP will stage Hong Kong Tech Pavilions at GITEX Global 2025 in Dubai
Oct 8, 2025 16:41 HKT/SGT
|
|
|
Open Dialogue Experts at NC 'Russia' Discuss Success Formula in the Economy of the Future
Oct 8, 2025 15:00 HKT/SGT
|
|
|
Fujitsu and ARYA develop high-precision AI solution for instant detection of suspicious behavior
Oct 8, 2025 14:39 JST
|
|
|
Toda, JTB and Fujitsu kick off NFT-powered digital transformation project to boost international tourism to Japan
Oct 8, 2025 13:39 JST
|
|
|
Fujitsu and Sony Bank partner to integrate generative AI into core banking system design and development
Oct 8, 2025 13:02 JST
|
|
|
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
Oct 8, 2025 12:03 JST
|
|
|
Sharp's 5G NTN-Compatible LEO Satellite Communication User Terminal Wins the Minister for Internal Affairs and Communications Award at CEATEC AWARD 2025
Oct 8, 2025 11:28 JST
|
|
|
SAP Business Suite Unites AI, Data and Applications to Power the Next Generation of Enterprise Transformation
Oct 8, 2025 10:15 HKT/SGT
|
|
|
SAPPE Brings Mogu Mogu to the Global Stage at Anuga 2025 Germany
Oct 8, 2025 08:00 HKT/SGT
|
|
|
Radisson Announces Closing of Brokered Financing for $25 Million
Oct 7, 2025 23:59 HKT/SGT
|
|
|
IICCS Forum 2025 Officially Opens: Indonesia Strengthens Its Position as a CCS Leader in the Asia-Pacific
Oct 7, 2025 21:00 HKT/SGT
|
|
|
Global Scams on the Rise: Over Half of Adults Worldwide Report Scam Encounters, 23% Lost Money
Oct 7, 2025 20:15 HKT/SGT
|
|
|
VirPoint.com Launches AI-Enhanced Trading Expansion, Strengthening CFD Brokerage Across Europe
Oct 7, 2025 16:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
